Core Viewpoint - Wantaibio is actively advancing the WHO PQ certification process for its nine-valent HPV vaccine following its approval, leveraging its existing international achievements with the two-valent HPV vaccine [1] Group 1 - The company has initiated a structured plan for nationwide bidding and procurement work for the nine-valent HPV vaccine after its approval [1] - Wantaibio is confident in accelerating the overseas access and expansion of the nine-valent HPV vaccine, supported by its global network and prior success in over 20 countries with its two-valent HPV vaccine [1] - The two-valent HPV vaccine has been included in immunization programs in eight countries, showcasing the company's established international presence [1]